AstraZeneca's Imfinzi gets EU nod for biliary tract cancer

TL;DR

EU panel backs AstraZeneca's Imfinzi for advanced bile duct cancer after chemo.

AI Summary

AstraZeneca PLC announced on May 27, 2025, that its Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) who have previously received chemotherapy. This recommendation is based on data from the TOPAZ-1 Phase III trial.

Why It Matters

This positive recommendation brings AstraZeneca's Imfinzi closer to market approval in the EU for a new cancer indication, potentially expanding treatment options for patients with biliary tract cancer.

Risk Assessment

Risk Level: low — The filing is a routine report of a positive regulatory recommendation, not indicating new financial risks.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report and developer of the drug
• Imfinzi (durvalumab) (drug) — The medication recommended for approval
• European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) (company) — Regulatory body that made the recommendation
• TOPAZ-1 Phase III trial (trial) — Clinical trial data supporting the recommendation

FAQ

From the Filing

0001654954-25-006101.txt : 20250527 0001654954-25-006101.hdr.sgml : 20250527 20250527060942 ACCESSION NUMBER: 0001654954-25-006101 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250527 FILED AS OF DATE: 20250527 DATE AS OF CHANGE: 20250527 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 25984098 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a0471k.htm IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER a0471k  FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of May 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F            X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __            No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________           AstraZeneca PLC   INDEX TO EXHIBITS     1.  Imfinzi recommended in EU for bladder cancer   27 May 2025   Imfinzi  recommended for approval in the EU by CHMP as first and only perioperative immunotherapy for  muscle-invasive bladder cancer    Recommendation based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone   AstraZeneca's  Imfinzi  (durvalumab)   has been recommended for approval in the European Union (EU) for the treatment of adult patients   with resectable muscle-invasive bladder cancer (MIBC)   in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by  Imfinzi  as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).   The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the   NIAGARA   Phase III trial, which were presented during a Presidential Symposium at the 2024 European Society for Medical Oncology (ESMO) Congress and simultaneously published in   The New England Journal of Medicine .   In a planned interim analysis, the  Imfinzi -based   perioperative regimen demonstrated a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus